When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated ...
Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...
Steve Grasso, CEO of Grasso Global, joins CNBC's 'The Exchange' to discuss outlooks on three stocks: Supermicro, Novo Nordisk ...
Novo Nordisk (NVO) has released an update. Novo Nordisk has successfully concluded a share repurchase program initiated on August 7, 2024, ...
CVS Caremark and Express Scripts, along with GoodRx and others, are accused of working together to suppress reimbursements to independent pharmacies in at least three class-action lawsuits. Also, Hims ...
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ascendis Pharma (ASND – Research ...
Madrigal’s Rezdiffra has launched a new MASH market, but ‘tremendous change’ is on the horizon
With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...
Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...
Novo Nordisk stock faces bearish technicals, but analysts forecast nearly 46% upside. Novo inks $285 million Ascendis deal, ...
As demand for popular weight-loss drugs like Wegovy and Zepbound skyrockets, patients are taking dosage amounts into their ...
BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback